Pâmella de Moura
Research Subjects
Research Interests
Pâmella de Moura has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alex Christian Manhaes
Laboratório de Neurofisiologia, Departamento de Ciências Fisiológicas, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Av. Prof. Manuel de Abreu 444, 5 Andar—Vila Isabel, Rio de Janeiro 20550-170, RJ, Brazil
1 shared publication - Danielle Dias Pinto Ferreira
Laboratório de Neurofarmacologia, Instituto Biomédico, Niterói, Brazil
1 shared publication - Gustavo Costa Ferreira
Laboratório de Erros Inatos do Metabolismo, Programa de Bioquímica e Biofísica Celular, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-599, Brazil
1 shared publication - Mariana Nunes Marinho Ritter Ferreira
Laboratório de Neurofarmacologia, Instituto Biomédico, Niterói, Brazil
1 shared publication - Matheus Figueiredo Sathler
Department of Biomedical Sciences, Colorado State University, Fort Collins, USA
1 shared publication - Maurício dos Santos Pereira
Laboratório de Neurofisiologia Molecular, Departamento de Morfologia, Fisiologia e Patologia Básica, Faculdade de Odontologia de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by Pro Reitoria de Pesquisa, Pos Graduacao e Inovacao - UFF in Neurociências & Sociedade
- Vol. 3 (1) , e026004
Persistir também é ter oportunidade
- 2 October 2026
- Published by Pro Reitoria de Pesquisa, Pos Graduacao e Inovacao - UFF in Neurociências & Sociedade
- Vol. 3 (1) , e026004
Open AccessPersistir também é ter oportunidade
- 12 October 2021
- Published by Springer Nature in Neurotoxicity Research
- Vol. 39 (6) , 1946-1958
Caffeine Improves GABA Transport in the Striatum of Spontaneously Hypertensive Rats (SHR)
The spontaneously hypertensive rat (SHR) is an excellent animal model that mimics the behavioral and neurochemical phenotype of attention-deficit/hyperactivity disorder (ADHD). Here, we characterized the striatal GABA transport of SHR and investigated whether caffeine, a non-selective antagonist of adenosine receptors, could influence GABAergic circuitry. For this purpose, ex vivo striatal slices of SHR and Wistar (control strain) on the 35th postnatal day were dissected and incubated with [3H]-GABA to quantify the basal levels of uptake and release. SHR exhibited a reduced [3H]-GABA uptake and release, suggesting a defective striatal GABAergic transport system. GAT-1 appears to be the primary transporter for [3H]-GABA uptake in SHR striatum, as GAT-1 selective blocker, NO-711, completely abolished it. We also verified that acute exposure of striatal slices to caffeine improved [3H]-GABA uptake and release in SHR, whereas Wistar rats were not affected. GABA-uptake increase and cAMP accumulation promoted by caffeine was reverted by A1R activation with N6-cyclohexyl adenosine (CHA). As expected, the pharmacological blockade of cAMP-PKA signaling by H-89 also prevented caffeine-mediated [3H]-GABA uptake increment. Interestingly, a single caffeine exposure did not affect GAT-1 or A1R protein density in SHR, which was not different from Wistar protein levels, suggesting that the GAT-1-dependent transport in SHR has a defective functional activity rather than lower protein expression. The current data support that caffeine regulates GAT-1 function and improves striatal GABA transport via A1R-cAMP-PKA signaling, specifically in SHR. These results reinforce that caffeine may have therapeutic use in disorders where the GABA transport system is impaired.
- 12 October 2021
- Published by Springer Nature in Neurotoxicity Research
- Vol. 39 (6) , 1946-1958
Caffeine Improves GABA Transport in the Striatum of Spontaneously Hypertensive Rats (SHR)
The spontaneously hypertensive rat (SHR) is an excellent animal model that mimics the behavioral and neurochemical phenotype of attention-deficit/hyperactivity disorder (ADHD). Here, we characterized the striatal GABA transport of SHR and investigated whether caffeine, a non-selective antagonist of adenosine receptors, could influence GABAergic circuitry. For this purpose, ex vivo striatal slices of SHR and Wistar (control strain) on the 35th postnatal day were dissected and incubated with [3H]-GABA to quantify the basal levels of uptake and release. SHR exhibited a reduced [3H]-GABA uptake and release, suggesting a defective striatal GABAergic transport system. GAT-1 appears to be the primary transporter for [3H]-GABA uptake in SHR striatum, as GAT-1 selective blocker, NO-711, completely abolished it. We also verified that acute exposure of striatal slices to caffeine improved [3H]-GABA uptake and release in SHR, whereas Wistar rats were not affected. GABA-uptake increase and cAMP accumulation promoted by caffeine was reverted by A1R activation with N6-cyclohexyl adenosine (CHA). As expected, the pharmacological blockade of cAMP-PKA signaling by H-89 also prevented caffeine-mediated [3H]-GABA uptake increment. Interestingly, a single caffeine exposure did not affect GAT-1 or A1R protein density in SHR, which was not different from Wistar protein levels, suggesting that the GAT-1-dependent transport in SHR has a defective functional activity rather than lower protein expression. The current data support that caffeine regulates GAT-1 function and improves striatal GABA transport via A1R-cAMP-PKA signaling, specifically in SHR. These results reinforce that caffeine may have therapeutic use in disorders where the GABA transport system is impaired.